Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib, L-NMMA, and Nab-paclitaxel in HER2-Negative Metaplastic Breast Cancer
NCT05660083Phase 2Recruiting
- Sponsor
- Houston Methodist Research Institute
- Start
- Jan 2023
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of alpelisib, NG-monomethyl-L-arginine in Metaplastic breast cancer (MpBC), sponsored by Houston Methodist Research Institute. Started Jan 2023; status: recruiting.
02
Drugs
alpelisibNG-monomethyl-L-arginine
03
Conditions
Metaplastic breast cancer (MpBC)
Beyond the preview
Go deeper on NCT05660083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05660083.